Literature DB >> 19878375

Underutilization of angiotensin-converting enzyme inhibitors in high-risk blacks: a case of missed opportunities.

Keith C Ferdinand1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19878375      PMCID： PMC8673044          DOI： 10.1111/j.1751-7176.2009.00187.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  12 in total

1.  Overlap between whites and blacks in response to antihypertensive drugs.

Authors:  Ashwini R Sehgal
Journal:  Hypertension       Date:  2004-02-02       Impact factor: 10.190

2.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

Review 3.  Coronary heart disease in African Americans.

Authors:  L T Clark; K C Ferdinand; J M Flack; J R Gavin; W D Hall; S K Kumanyika; J W Reed; E Saunders; H A Valantine; K Watson; N K Wenger; J T Wright
Journal:  Heart Dis       Date:  2001 Mar-Apr

4.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.

Authors:  Carl J Pepine; Eileen M Handberg; Rhonda M Cooper-DeHoff; Ronald G Marks; Peter Kowey; Franz H Messerli; Giuseppe Mancia; José L Cangiano; David Garcia-Barreto; Matyas Keltai; Serap Erdine; Heather A Bristol; H Robert Kolb; George L Bakris; Jerome D Cohen; William W Parmley
Journal:  JAMA       Date:  2003-12-03       Impact factor: 56.272

5.  Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.

Authors:  Kenneth Jamerson; Michael A Weber; George L Bakris; Björn Dahlöf; Bertram Pitt; Victor Shi; Allen Hester; Jitendra Gupte; Marjorie Gatlin; Eric J Velazquez
Journal:  N Engl J Med       Date:  2008-12-04       Impact factor: 91.245

6.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

7.  Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients.

Authors:  Michael H Alderman; Hillel W Cohen; Jean E Sealey; John H Laragh
Journal:  Am J Hypertens       Date:  2004-01       Impact factor: 2.689

Review 8.  Recommendations for the management of special populations: racial and ethnic populations.

Authors:  Keith C Ferdinand
Journal:  Am J Hypertens       Date:  2003-11       Impact factor: 2.689

9.  An international comparative study of blood pressure in populations of European vs. African descent.

Authors:  Richard S Cooper; Katharina Wolf-Maier; Amy Luke; Adebowale Adeyemo; José R Banegas; Terrence Forrester; Simona Giampaoli; Michel Joffres; Mika Kastarinen; Paola Primatesta; Birgitta Stegmayr; Michael Thamm
Journal:  BMC Med       Date:  2005-01-05       Impact factor: 8.775

10.  Protective effects of angiotensin-converting enzyme inhibitors in high-risk African American men with coronary heart disease.

Authors:  Vasilios Papademetriou; Christodoulos Kaoutzanis; Michael Dumas; Andreas Pittaras; Charles Faselis; Peter Kokkinos; Ross D Fletcher
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-11       Impact factor: 3.738
View more
  1 in total

1.  Adrenergic alpha-1 pathway is associated with hypertension among Nigerians in a pathway-focused analysis.

Authors:  Nicholas P Reder; Bamidele O Tayo; Babatunde Salako; Adesola Ogunniyi; Adebowale Adeyemo; Charles Rotimi; Richard S Cooper
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.